

**MISSISSIPPI DIVISION OF MEDICAID (DOM)  
TOP 25 DRUGS BY PAYMENT IN 2014  
INFORMATION FOR SENATE COMMITTEE REQUEST**

Table 1 provides average monthly enrollment statistics for calendar year 2014. During 2014, approximately 25% of non-long term care beneficiaries with pharmacy benefits were enrolled in managed care programs.

<b>TABLE 1: Enrollment Statistics 2014</b>		Average Monthly
Total enrollment		703,015
Dual-eligibles		153,252
Pharmacy benefits		605,145
Long Term Care (LTC)		17,533
NON-LTC	FFS	437,771 (74.5%)
	Managed Care	150,429 (25.6%)

Tables 2-4 lists the top 25 drugs by amount paid in 2014 for the entire Mississippi Medicaid program, the Fee-for-service (FFS) program and the managed care program, respectively. Information for Sovaldi® or Harvoni® are also included in the tables when the products are not in the top 25.

**IMPORTANT NOTES:**

- Generic names and brand names for each drug entity are listed in the tables to help in identifying drugs products.
- The reported number of claims and amount paid are for the entire drug entity including all strengths and dosage forms. Therefore, there are no associated WACs.
- The percentage of claims dispensed as brand and generic will vary for some drug entities due to differences in preferred drugs.
- Amounts paid reflect the total reimbursement amount (cost of product and dispensing fee) paid to pharmacies.
- In 2014, the FFS and managed care programs did not have a universal preferred drug list; therefore, utilization and amounts paid for each drug entity may vary significantly between the two program types.
- Actual Medicaid costs for fee-for-service claims will be significantly less due to Federal and state special rebates paid by manufacturers.

Mississippi Medicaid entered into a supplemental rebate agreement, for both fee for service and coordinated/managed care pharmacy claims, with Gilead Sciences, Inc. for Sovaldi® effective January 1, 2015. A supplemental rebate agreement, for both fee for service and coordinated/managed care pharmacy claims, is scheduled for Harvoni® starting April 1, 2015.

Table 2 lists the top 25 drugs by amount paid in 2014 for the **entire Mississippi Medicaid program**.

- Sofosbuvir ranked 11<sup>th</sup> in overall program payments.
- Ledipasvir/sofosbuvir ranked 185 in overall program payments.

Table 3 lists the top 25 drugs by amount for the **fee-for-service program** only.

- Sofosbuvir ranked 28<sup>th</sup> in the FFS population.
- Ledipasvir/sofosbuvir ranked 250 in FFS payments.

Table 4 lists the top 25 drugs by amount paid by the two **managed care plans** in the state.

- Sofosbuvir ranked 3<sup>rd</sup> in the managed care population.
- Ledipasvir/sofosbuvir ranked 131 in managed care payments.

**TABLE 2: Mississippi Medicaid Total Population  
Top 25 Drugs by Dollars Paid - Calendar Year 2014  
(Includes fee-for-service and managed care)**

Rank	Generic Name	Brand Name	Therapeutic Category	Number of Beneficiaries	Number of Claims	Dollars Paid
1	MONTELUKAST	SINGULAIR	LEUKOTRIENE MODIFIERS	36,874	106,710	\$18,841,042
2	ARIPIPIRAZOLE	ABILIFY	ATYPICAL ANTIPSYCHOTICS	4,331	22,396	\$16,129,143
3	LISDEXAMFETAMINE	VYVANSE	CNS STIMULANTS	13,581	71,290	\$14,933,855
4	QUETIAPINE	SEROQUEL	ATYPICAL ANTIPSYCHOTICS	5,638	28,464	\$11,484,285
5	METHYLPHENIDATE	RITALIN	CNS STIMULANTS	12,162	63,851	\$10,543,722
6	AMPHETAMINE- DEXTROAMPHETAMINE	AMPHETAMINE- DEXTROAMPHETAMINE	CNS STIMULANTS	10,277	61,120	\$9,121,174
7	ANTIHEMOPHILIC FACTOR	XYNTHA	MISC COAGULATION MODIFIERS	56	453	\$8,557,671
8	BUDESONIDE	UCERIS	GLUCOCORTICOIDS	10,188	20,170	\$8,422,866
9	INSULIN GLARGINE	LANTUS	INSULIN	4,426	20,530	\$7,935,957
10	ALBUTEROL	VENTOLIN	ADRENERGIC BRONCHODILATORS	73,757	168,733	\$7,867,485
11	SOFOSBUVIR	SOVALDI	NRTIS	87	266	\$7,667,015
12	GUANFACINE	TENEX	ANTIADRENERGIC AGENTS, CENTRALLY ACTING	9,130	45,810	\$6,916,340
13	SOMATROPIN	TEV-TROPIN	GROWTH HORMONES	239	1,781	\$6,776,796
14	MOMETASONE NASAL	NASONEX	NASAL STEROIDS	21,592	37,083	\$6,404,921
15	OSELTAMIVIR	TAMIFLU	NEURAMINIDASE INHIBITORS	32,363	33,719	\$5,889,197
16	OLANZAPINE	ZYPREXA	ATYPICAL ANTIPSYCHOTICS	1,962	11,151	\$5,730,326
17	DEXMETHYLPHENIDATE	FOCALIN	CNS STIMULANTS	4,798	27,995	\$5,508,700
18	ACETAMINOPHEN- HYDROCODONE	ACETAMINOPHEN- HYDROCODONE	NARCOTIC ANALGESIC COMB.	76,507	230,403	\$5,068,212
19	FLUTICASONE-SALMETEROL	ADVAIR	BRONCHODILATOR COMB.	5,122	16,754	\$5,021,782
20	EFAVIRENZ/EMTRICITABINE /TENOFVIR	ATRIPLA	ANTIVIRAL COMBINATIONS	327	2,331	\$4,926,197
21	PALIVIZUMAB	SYNAGIS	IMMUNE GLOBULINS	850	2,142	\$4,737,546
22	ANTI-INHIBITOR COAG. COM.	FEIBA	MISC COAGULATION MODIFIERS	8	35	\$4,602,756
23	RISPERIDONE	RISPERIDONE	ATYPICAL ANTIPSYCHOTICS	8,826	46,530	\$4,462,598
24	AMOXICILLIN-CLAVULANATE	AUGMENTIN	BETA-LACTAMASE INHIBITORS	58,373	74,958	\$4,381,274
25	OMEPRAZOLE	PRIOSEC	PROTON PUMP INHIBITORS	20,223	70,915	\$4,335,388
185	LEDIPASVIR/SOFOSBUVIR	HARVONI	NRTIS	8	12	\$399,179

**TABLE 3: Mississippi Medicaid Fee-For-Service  
Top 25 Drugs by Dollars Paid - Calendar Year 2014**

Rank	Generic Name	Brand Name	Therapeutic Category	Number of Beneficiaries	Number of Claims	Dollars Paid
1	MONTELUKAST	SINGULAIR	LEUKOTRIENE MODIFIERS	31,259	90,950	\$17,241,847
2	LISDEXAMFETAMINE	VYVANSE	CNS STIMULANTS	12,080	63,300	\$13,230,009
3	METHYLPHENIDATE	RITALIN	CNS STIMULANTS	9,918	52,819	\$8,863,771
4	ARIPIPRAZOLE	ABILIFY	ATYPICAL ANTIPSYCHOTICS	2,910	13,755	\$8,827,791
5	ANTIHEMOPHILIC FACTOR	XYNTHA	MISC COAGULATION MODIFIERS	56	453	\$8,557,671
6	BUDESONIDE	UCERIS	GLUCOCORTICIODS	8,298	16,369	\$7,245,709
7	AMPHETAMINE - DEXTROAMPHETAMINE	AMPHETAMINE - DEXTROAMPHETAMINE	CNS STIMULANTS	7,419	44,345	\$7,009,244
8	MOMETASONE NASAL	NASONEX	NASAL STEROIDS	21,230	36,437	\$6,294,047
9	GUANFACINE	TENEX	ANTIADRENERGIC AGENTS, CENTRALLY ACTING	7,497	37,485	\$6,105,136
10	QUETIAPINE	SEROQUEL	ATYPICAL ANTIPSYCHOTICS	2,389	12,267	\$5,420,242
11	SOMATROPIN	TEV-TROPIN	GROWTH HORMONES	182	1,398	\$5,284,589
12	ALBUTEROL	VENTOLIN	ADRENERGIC BRONCHODILATORS	50,880	109,472	\$5,228,780
13	DEXMETHYLPHENIDATE	FOCALIN	CNS STIMULANTS	4,471	25,768	\$5,087,734
14	OSELTAMIVIR	TAMIFLU	NEURAMINIDASE INHIBITORS	26,283	27,427	\$5,000,500
15	ANTI-INHIBITOR COAGULANT COMPLEX	FEIBA	MISC COAGULATION MODIFIERS	8	35	\$4,602,756
16	ESOMEPRAZOLE	NEXIUM	PROTON PUMP INHIBITORS	4,855	13,420	\$3,422,507
17	AMOXICILLIN -CLAVULANATE	AUGMENTIN	BETA-LACTAMASE INHIBITORS	41,828	53,015	\$3,333,537
18	AZITHROMYCIN	ZITHROMAX	MACROLIDES	71,589	98,946	\$3,260,184
19	CETIRIZINE	ZYRTEC HIVES	ANTI HISTAMINES	75,936	153,301	\$2,919,444
20	ONDANSETRON	ZOFRAN	5HT3 RECEPTOR ANTAGONISTS	23,408	28,066	\$2,844,349
21	FLUTICASONE -SALMETEROL	ADVAIR	BRONCHODILATOR COMBINATIONS	3,100	9,492	\$2,731,818
22	CEFDINIR	CEFDINIR	3RD GEN. CEPHALOSPORINS	25,421	32,888	\$2,703,532
23	RISPERIDONE	RISPERIDONE	ATYPICAL ANTIPSYCHOTICS	4,678	25,025	\$2,428,579
24	OLANZAPINE	ZYPREXA	ATYPICAL ANTIPSYCHOTICS	741	4,758	\$2,325,944
25	INSULIN GLARGINE	LANTUS	INSULIN	1,490	6,470	\$2,286,253
28	SOFOSBUVIR	SOVALDI	NRTIS	23	66	\$1,951,548
250	LEDIPASVIR/SOFOSBUVIR	HARVONI	NRTIS	2	3	\$99,795

**TABLE 4: Mississippi Medicaid Managed Care  
Top 25 Drugs by Dollars Paid - Calendar Year 2014**

Rank	Generic Name	Brand Name	Therapeutic Category	Number of Beneficiaries	Number of Claims	Dollars Paid
1	ARIPIRAZOLE	ABILIFY	ATYPICAL ANTIPSYCHOTICS	1,623	8,641	\$7,301,352
2	QUETIAPINE	SEROQUEL	ATYPICAL ANTIPSYCHOTICS	3,613	16,197	\$6,064,043
3	SOFOSBUVIR	SOVALDI	NRTIS	66	200	\$5,715,467
4	INSULIN GLARGINE	LANTUS	INSULIN	3,180	14,060	\$5,649,705
5	EFAVIRENZ /EMTRICITABINE /TENOFIVIR	ATRIPLA	ANTIVIRAL COMBINATIONS	276	1,946	\$4,124,882
6	ACETAMINOPHEN - HYDROCODONE	ACETAMINOPHEN - HYDROCODONE	NARCOTIC ANALGESIC COMB.	50,902	176,273	\$3,949,013
7	OMEPRAZOLE	PRILOSEC	PROTON PUMP INHIBITORS	16,558	62,989	\$3,803,292
8	PALIVIZUMAB	SYNAGIS	IMMUNE GLOBULINS	679	1,651	\$3,731,667
9	OLANZAPINE	ZYPREXA	ATYPICAL ANTIPSYCHOTICS	1,311	6,393	\$3,404,382
10	ALBUTEROL	VENTOLIN	ADRENERGIC BRONCHODILATORS	25,113	59,261	\$2,638,706
11	ADALIMUMAB	HUMIRA	TNF ALFA INHIBITORS	121	806	\$2,475,140
12	EMTRICITABINE -TENOFIVIR	TRUVADA	ANTIVIRAL COMBINATIONS	295	1,806	\$2,411,664
13	FLUTICASONE -SALMETEROL	ADVAIR	BRONCHODILATOR COMBINATIONS	2,141	7,262	\$2,289,964
14	DEFERASIROX	EXJADE	CHELATING AGENTS	67	301	\$2,281,397
15	GABAPENTIN	GABAPENTIN	GAMMA-AMINOBUTYRIC ACID ANALOGS	13,471	56,233	\$2,212,499
16	AMPHETAMINE - DEXTROAMPHETAMINE	AMPHETAMINE - DEXTROAMPHETAMINE	CNS STIMULANTS	3,270	16,775	\$2,111,930
17	CORTICOTROPIN	ACTHAR GEL	CORTICOTROPIN	19	51	\$2,102,037
18	RISPERIDONE	RISPERIDONE	ATYPICAL ANTIPSYCHOTICS	4,578	21,505	\$2,034,020
19	BUPRENORPHINE - NALOXONE	SUBOXONE	NARCOTIC ANALGESIC COMB.	886	5,233	\$1,949,951
20	INSULIN ASPART	NOVOLOG	INSULIN	1,300	5,055	\$1,839,995
21	ATAZANAVIR	REYATAZ	PROTEASE INHIBITORS	228	1,431	\$1,752,441
22	DIVALPROEX SODIUM	DIVALPROEX SODIUM	FATTY ACID DERIVATIVE ANTICONVULSANTS	3,053	14,969	\$1,719,891
23	LISDEXAMFETAMINE	VYVANSE	CNS STIMULANTS	1,859	7,990	\$1,703,845
24	METHYLPHENIDATE	RITALIN	CNS STIMULANTS	2,594	11,032	\$1,679,951
25	MONTELUKAST	SINGULAIR	LEUKOTRIENE MODIFIERS	6,185	15,760	\$1,599,194
131	LEDIPASVIR/SOFOSBUVIR	HARVONI	NRTIS	6	9	\$299,384